Acute Effects of Intradialytic Exercise on Cardiovascular Function in Hemodialysis Patients

Overview

The purpose of this study is to examine the effect of cycling at mild to moderate intensity during hemodialysis treatment on cardiovascular function in a crossover design.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Supportive Care
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2016

Detailed Description

Patients with kidney failure requiring hemodialysis (HD) treatment die at excessively high rates, despite advances in HD techniques and pharmacological therapies. This indicates additional therapeutic strategies are needed. Intradialytic exercise (IDEX, exercise during HD treatment) represents a low-cost, easy to administer treatment strategy that could potentially improve cardiovascular function, physical function and quality of life. However, nephrologists rarely counsel their patients to increase their physical activity levels or to exercise during HD treatment, in part due to a lack of understanding of IDEX knowledge. Providing more robust evidence for the safety and effectiveness of IDEX, as well as evaluating the impact of exercising early vs late in the treatment, could help improve adoption of exercise training as a standard practice in HD clinics. Therefore, investigators plan to examine the impact of IDEX and its timing during treatment (1st vs 3rd hour) on blood pressure and adverse symptoms in HD patients. The proposed study also includes various cardiovascular measures to allow deeper mechanistic understanding of cardiovascular physiology with IDEX. Such understanding will significantly advance the field and lead to improved therapeutic approaches, including exercise training, which may help mediate the deleterious effects of renal failure.

Interventions

  • Behavioral: exercise
    • Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment
  • Procedure: Hemodialysis treatment
    • Participants will receive a standard hemodialysis treatment during the study period

Arms, Groups and Cohorts

  • Experimental: Standard Hemodialysis
    • Participants will be monitored during their normal hemodialysis treatment with no intervention administered
  • Experimental: Hemodialysis with Exercise (1-st hr)
    • Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 1-st hour into treatment
  • Experimental: Hemodialysis with Exercise (3-rd hr)
    • Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 3-rd hour into treatment

Clinical Trial Outcome Measures

Primary Measures

  • Serial change in brachial blood pressure (mmHg) from start to end of a dialysis treatment
    • Time Frame: Every 15 minutes throughout each dialysis treatment (approximately 4 hours)
    • Systolic and diastolic blood pressure will be measured using an automated blood pressure cuff attached to the clinic dialysis machine
  • Changes in cardiac output (mL/min) measured by thoracic impedance technique
    • Time Frame: Continous throughout a dialysis treatment (approximately 4 hours)
    • Cardiac output will be estimated continuously using thoracic impedance with electrodes placed around the chest.

Secondary Measures

  • Changes in total peripheral resistance estimated by peripheral blood pressure via a finger plethysmography and cardiac output via thoracic impedance (Task Force Monitor)
    • Time Frame: Continuous throughout each dialysis treatment (approximately 4 hours) for three dialysis sessions that are separated by a week
    • A finger cuff will be placed around the non-dialyzing finger and will measure the change in peripheral blood pressure from successive beats continuously. Total peripheral resistance will be estimated using measured cardiac output and peripheral blood pressure.
  • Hypotensive event assessment measured by a symptom questionnaire
    • Time Frame: Throughout and up to 5 hours after completion of a dialysis treatment
    • The presence of hypotensive-relating intradialytic symptoms including nausea, dizziness and cramping will be recorded.

Participating in This Clinical Trial

Inclusion Criteria

  • Receiving hemodialysis treatment three times per week, on hemodialysis for greater than three months, receive medical clearance from a Nephrologists Exclusion Criteria:

  • Patients with established contraindications to exercise including lower-limb amputation, advanced chronic obstructive pulmonary disease and decompensated chronic heart failure.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Illinois at Urbana-Champaign
  • Provider of Information About this Clinical Study
    • Principal Investigator: Kenneth Wilund, Associate Professor – University of Illinois at Urbana-Champaign
  • Overall Official(s)
    • Kenneth Wilund, PhD, Principal Investigator, University of Illinois at Urbana-Champaign

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.